Show simple item record

dc.contributor.authorGokani, Ben_US
dc.contributor.authorSacoor, Sen_US
dc.contributor.authorLeisegang, GRen_US
dc.contributor.authorOgunkolade, Wen_US
dc.contributor.authorBibi, Aen_US
dc.contributor.authorGrigoriadou, Sen_US
dc.contributor.authorPade, Cen_US
dc.contributor.authorGibbons, Jen_US
dc.contributor.authorSenusi, Aen_US
dc.contributor.authorFortune, Fen_US
dc.date.accessioned2024-02-14T09:55:08Z
dc.date.available2023-07-18en_US
dc.date.issued2023en_US
dc.identifier.issn1521-6616en_US
dc.identifier.otherARTN 109700
dc.identifier.otherARTN 109700
dc.identifier.otherARTN 109700en_US
dc.identifier.otherARTN 109700en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/94626
dc.relation.ispartofCLINICAL IMMUNOLOGYen_US
dc.subjectBehcet's disease responseen_US
dc.subjectSARS-CoV-2en_US
dc.subjectCOVID-19 vaccinesen_US
dc.subjectAnti -spike IgGen_US
dc.subjectNucleocapsid IgGen_US
dc.subjectImmunosuppressive medicationen_US
dc.titleBehcet's patients' response to COVID-19 vaccinationen_US
dc.typeArticle
dc.rights.holder2023 Elsevier Inc. All rights reserved.
dc.identifier.doi10.1016/j.clim.2023.109700en_US
pubs.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:001052206100001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume255en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
qmul.funderTowards drug development: mechanistic insight into REAF/TASOR restriction and Vpr mediated counter-restriction.::Barts Charityen_US
qmul.funderTowards drug development: mechanistic insight into REAF/TASOR restriction and Vpr mediated counter-restriction.::Barts Charityen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record